To include your compound in the COVID-19 Resource Center, submit it here.

Tyme reports Phase I data of SM-88 in metastatic cancer

Tyme Technologies Inc. (NASDAQ:TYME) reported data from an open-label Phase I trial in 30

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE